Physician

Jigar Shah, M.D.

According to 2025 Medicare claims, Jigar Shah, M.D. (NPI: 1659508166) practices internal medicine in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (NPI: 1598205072; TIN: 831053374) and primary practice location at 33063-5683. Shah is affiliated with the Sound Physicians Long Term Care Management, LLC (ACO ID: A5220), participating under the MSSP model.

Shah's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 348 traditional Medicare patients, billed 134,126 HCPCS/CPT codes, and received $1,955,986 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 2,490 prescription claims across 550 beneficiaries totaling $2,985,116 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 357 records totaling $1,155,274. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $20,086 to $1,955,986. Similarly, Part D prescription costs have risen steadily, from $12,292 to $2,985,116. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	155	479	$20,086
2016	326	3,985	$156,572
2017	278	8,107	$207,189
2018	234	19,459	$319,097
2019	213	33,323	$808,960
2020	222	45,530	$1,214,635
2021	288	63,734	$1,026,765
2022	319	92,942	$1,169,898
2023	336	105,033	$1,340,016
2024	348	134,126	$1,955,986

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	50	80	$12,292
2016	320	1,673	$737,028
2017	432	2,549	$1,602,172
2018	364	1,386	$909,053
2019	342	1,600	$1,313,969
2020	405	2,144	$865,133
2021	549	3,010	$1,788,893
2022	628	3,323	$3,790,557
2023	601	2,727	$5,002,354
2024	550	2,490	$2,985,116

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	102	102	$136
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	242	545	$106
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	149	218	$74
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	113	690	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	227	421	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	61	1,708	$427,628
Rinvoq	Upadacitinib	46	1,380	$297,661
Enbrel Mini	Etanercept	28	784	$220,189
Remicade	Infliximab	26	1,161	$176,591
Tymlos	Abaloparatide	50	1,480	$140,420

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	283	$165,952	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	74	$989,323	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jigar Shah, M.D.?

Tedicare shows public-source Medicare data for Jigar Shah, M.D. (NPI 1659508166), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jigar Shah, M.D. have ACO affiliation data?

Jigar Shah, M.D. is shown with ACO affiliation data for Sound Physicians Long Term Care Management, LLC (MSSP, ACO ID A5220).

What billing organization is linked to Jigar Shah, M.D.?

Jigar Shah, M.D. is linked to AMERICAN ARTHRITIS & RHEUMATOLOGY ASSOCIATES LLC (billing NPI 1598205072) in the available physician profile data.

Does Jigar Shah, M.D. have Open Payments data?

Jigar Shah, M.D. has 357 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.